Repositioning of ETO gene in cells treated with VP-16, an inhibitor of DNA-topoisomerase II

Journal of Cellular Biochemistry
Mikhail A RubtsovOlga V Iarovaia

Abstract

The translocation t(8;21)(q22;q22) affecting AML1 and ETO genes is known to be one of the frequent chromosome translocations in acute myeloid leukemia. But no data have been available up to date concerning mutual positioning of these particular genes in the nucleus of a living cell as well as the mechanism of their rapprochement and realignment. Here we show that there is no proximity between these two genes in the primary nuclei of normal human male fibroblasts and moreover that these genes are located in different nuclear layers. But we further show that treatment of cells with VP-16 (etoposide), an inhibitor of DNA topoisomerase II widely used in anticancer chemotherapy, causes the ETO gene repositioning which allows AML1 and ETO genes to be localized in the same nuclear layer. Inhibitor studies demonstrate that such an effect is likely to be connected with the formation of stalled cleavable complexes on DNA. Finally, inhibition of ETO gene repositioning by 2,3-butanedione monoxime (BDM) suggests that this process depends on nuclear myosin. Together, our data corroborate the so called "breakage first" model of the origins of recurrent reciprocal translocation.

References

Jun 16, 1989·Cell·S HandeliH Cedar
Jan 1, 1989·Annual Review of Biochemistry·L F Liu
Dec 17, 1989·Biochimica Et Biophysica Acta·P D'Arpa, L F Liu
Jan 1, 1994·Annual Review of Pharmacology and Toxicology·A Y Chen, L F Liu
Jun 1, 1993·Anti-cancer Drugs·H TsujimotoT Takahashi
Sep 28, 1998·Biochimica Et Biophysica Acta·C A Felix
Jun 15, 1999·The Journal of Cell Biology·J A CroftW A Bickmore
Feb 24, 2001·Science·J R Savage
Apr 3, 2001·Nature Reviews. Genetics·T Cremer, C Cremer
Feb 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yanming ZhangJanet D Rowley
Mar 28, 2002·Cellular and Molecular Life Sciences : CMLS·B Elliott, M Jasin
Jun 4, 2002·Nature Reviews. Molecular Cell Biology·James C Wang
Oct 4, 2002·Current Biology : CB·Luis A ParadaTom Misteli
Jun 17, 2003·Nature Genetics·Jeffrey J RoixTom Misteli
Oct 7, 2003·Annual Review of Biochemistry·David L Spector
Apr 17, 2004·Nucleic Acids Research·Olga V IarovaiaSergey V Razin
Aug 31, 2004·Genes, Chromosomes & Cancer·Yanming ZhangJanet D Rowley
Sep 15, 2004·The Journal of Cell Biology·Daniele ZinkDirk Schindelhauer
Apr 5, 2005·Cancer Research·Emanuela RoccatoAngela Greco
Jun 27, 2006·DNA Repair·Sheba AgarwalRoland Kanaar
Aug 9, 2006·DNA Repair·Yanming Zhang, Janet D Rowley
May 9, 2007·Nature Cell Biology·Evi SoutoglouTom Misteli

❮ Previous
Next ❯

Citations

Mar 5, 2009·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Omar L Kantidze, Sergey V Razin
Dec 12, 2013·Genes, Chromosomes & Cancer·Kayleigh A SmithCaroline A Austin
Nov 19, 2014·Molecular Cancer·Olga V IarovaiaYegor S Vassetzky

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.